Branched‐Chain α Keto‐Acid Dehydrogenase Kinase‐Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance
Advanced Science · 2025
DOI: 10.1002/advs.202411081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Qin Tian und 18 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Digestive Cancer Research, Precision Medicine Center, The Biobank, Scientific Research Center, The Seventh Aff…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Proto-Oncogene Proteins c-akt, Drug Resistance, Neoplasm, Kidney Neoplasms. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Key-Area Research and Development Program of Guangdong Province.
Abstract (Originalsprache)
Advanced renal cell carcinoma (RCC) primarily relies on targeted and immune‐based therapies, yet these treatments often face limitations due to inefficacy and drug resistance. Branched‐chain α‐keto‐acid dehydrogenase kinase (BCKDK) has been implicated in promoting RCC metastasis, but its specific substrates and the mechanisms underlying its regulation of RCC progression remain poorly understood. This study uncovers a novel mechanism whereby BCKDK‐mediated AKT phosphorylation drives RCC tumorigenesis and drug resistance. Elevated BCKDK expression correlates with poor prognosis in RCC clinical samples. BCKDK deficiency inhibits RCC cell proliferation and tumorigenesis both in vitro and in vivo. Mechanistic investigations reveal that BCKDK directly binds to and regulates the phosphorylation of AKT. BCKDK‐mediated phosphorylation of AKT decreases ubiquitin‐mediated AKT protein degradation, and promotes tumorigenesis via activation of the AKT/mTOR signaling pathway. RNA sequencing identifies BCKDK's involvement in the drug metabolism network and apoptotic signaling pathways. The BCKDK/AKT/ABCB1 axis mediates doxorubicin resistance. Targeting BCKDK/AKT inhibits the growth of RCC patient‐derived organoids (PDOs), enhances doxorubicin‐induced apoptosis in RCC cells, and suppresses tumor growth in vivo. These findings identify a previously unrecognized phosphorylation substrate of BCKDK and highlight the critical role of the BCKDK/AKT signaling axis in RCC progression, offering a promising target for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Digestive Cancer Research, Precision Medicine Center, The Biobank, Scientific Research Center, The Seventh Affiliated Hospital, School of Medicine, Sun Yat-Sen University, Shenzhen…
- Department of Orthopaedic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
- The Pharmacy College of Jiangxi Science and Technology Normal University, Nanchang, Jiangxi, 330013, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
- Biobank, Shenzhen Second People's Hospital, Shenzhen, Guangdong, 518035, China.
- Department of Nephrology, Center of Kidney and Urology, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
ORCID-Profile: Yihang Pan
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Key-Area Research and Development Program of Guangdong Province
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Science and Technology Program
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Tian, Q., Wang, J., Li, Q., Liu, Y., Chen, Y., Feng, J., Lei, Z. N., Patel, H., Cai, C. Y., Xu, Y., Quan, C., Fei, L., Xiao, Z., Fang, S., Lin, T., Chen, Z. S., Liu, Y., Zeng, L., & Pan, Y. (2025). Branched‐Chain α Keto‐Acid Dehydrogenase Kinase‐Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance. Advanced Science. https://doi.org/10.1002/advs.202411081
Vancouver
Tian Q, Wang J, Li Q, Liu Y, Chen Y, Feng J, et al. Branched‐Chain α Keto‐Acid Dehydrogenase Kinase‐Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance. Advanced Science. 2025. doi:10.1002/advs.202411081
BibTeX
@article{Tian2025,
author = {Tian, Qin and Wang, Jinxiang and Li, Qiji and Liu, Yangruiyu and Chen, Yanping and Feng, Jiacheng and Lei, Zi-Ning and Patel, Harsh and Cai, Chao-Yun and Xu, Yuzhi and Quan, Chuntao and Fei, Lingyan and Xiao, Zexiu and Fang, Shuo and Lin, Tianxin and Chen, Zhe-Sheng and Liu, Yuchen and Zeng, Leli and Pan, Yihang},
title = {Branched‐Chain α Keto‐Acid Dehydrogenase Kinase‐Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411081}
}
EUVIMED